Compare TOUR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOUR | XLO |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2M | 56.9M |
| IPO Year | 2014 | 2021 |
| Metric | TOUR | XLO |
|---|---|---|
| Price | $4.99 | $9.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.4K | ★ 7.6K |
| Earning Date | 08-25-2026 | 11-12-2026 |
| Dividend Yield | ★ 24.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $3.00 | N/A |
| P/E Ratio | $87.34 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.56 | $0.46 |
| 52 Week High | $7.79 | $9.90 |
| Indicator | TOUR | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 47.69 |
| Support Level | $4.93 | $8.63 |
| Resistance Level | $5.31 | $9.15 |
| Average True Range (ATR) | 0.11 | 0.24 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 0.00 | 5.41 |
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. The company offers a large selection of packaged tours, including organized tours and self-guided tours, and travel-related services for leisure travellers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.